Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | The MAGIC algorithm probability: a novel response biomarker for acute GvHD

Hrishikesh Srinagesh and James Ferrara • 7 Dec 2019
ASH 2019
General

Hrishikesh Srinagesh, BA, and James Ferrara, MD, DSc, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, discuss the Mount Sinai Acute GvHD International Consortium (MAGIC) algorithm probability (MAP) that combines serum concentrations of two biomarkers (REG3α and ST2) of graft versus host disease (GvHD). Results show that MAP is a more accurate predictor of survival than clinical response after four weeks of treatment and may serve as a novel endpoint in GvHD treatment trials. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from James Ferrara

2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
0:46
ST2 and REG3α as predictive biomarkers for GvHD
James Ferrara • 24 Apr 2023
1:54
A novel clinical trial endpoint for acute GvHD
James Ferrara • 24 Apr 2023
0:42
Vedolizumab for GI acute GvHD prophylaxis after allogeneic transplantation
James Ferrara • 24 Apr 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals